EcoDrugPlus

5-Hydroxytryptamine Receptor 1a

Ensembl ID : ENSJJAG00000016194
Gene Symbol: HTR1A
3 Cross references
147 Possible Orthologues:

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSJJAG00000018451
Gene Symbol: HTR1B
3 Cross references
245 Possible Orthologues:

5-Hydroxytryptamine Receptor 1f

Ensembl ID : ENSJJAG00000013994
Gene Symbol: HTR1F
3 Cross references
145 Possible Orthologues:

5-Hydroxytryptamine Receptor 2a

Ensembl ID : ENSJJAG00000005538
Gene Symbol: HTR2A
3 Cross references
218 Possible Orthologues:

5-Hydroxytryptamine Receptor 2b

Ensembl ID : ENSJJAG00000016268
Gene Symbol: HTR2B
3 Cross references
204 Possible Orthologues:

5-Hydroxytryptamine Receptor 2c

Ensembl ID : ENSJJAG00000024036
Gene Symbol: HTR2C
3 Cross references
226 Possible Orthologues:

5-Hydroxytryptamine Receptor 3a

Ensembl ID : ENSJJAG00000021347
Gene Symbol: HTR3A
3 Cross references
205 Possible Orthologues:

5-Hydroxytryptamine Receptor 3b

Ensembl ID : ENSJJAG00000008134
Gene Symbol: HTR3B
3 Cross references
174 Possible Orthologues:

5-Hydroxytryptamine Receptor 4

Ensembl ID : ENSJJAG00000017156
Gene Symbol: HTR4
3 Cross references
200 Possible Orthologues:

5-Hydroxytryptamine Receptor 5a

Ensembl ID : ENSJJAG00000019192
Gene Symbol: HTR5A
3 Cross references
210 Possible Orthologues:

5-Hydroxytryptamine Receptor 6

Ensembl ID : ENSJJAG00000019513
Gene Symbol: HTR6
3 Cross references
114 Possible Orthologues:

5-Hydroxytryptamine Receptor 7

Ensembl ID : ENSJJAG00000017934
Gene Symbol: HTR7
3 Cross references
219 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).